Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;56(1):180-181.
doi: 10.1111/apt.16931.

Letter: non-invasive prediction models to exclude cirrhosis in NAFLD - not everyone fits the mould

Suprabhat Giri  1 , Dhiraj Agrawal  2 , Shivaraj Afzalpurkar  3
Affiliations
Comment

Letter: non-invasive prediction models to exclude cirrhosis in NAFLD - not everyone fits the mould

Suprabhat Giri et al. Aliment Pharmacol Ther. 2022 Jul.
No abstract available

PubMed Disclaimer

Comment in

Comment on

  • Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
    Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Brandman D, et al. Aliment Pharmacol Ther. 2022 Jun;55(11):1441-1451. doi: 10.1111/apt.16874. Epub 2022 Mar 17. Aliment Pharmacol Ther. 2022. PMID: 35302256 Free PMC article.

References

REFERENCES

    1. Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, et al. Members of the nonalcoholic steatohepatitis clinical research network. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2022;55:1441-1451.
    1. Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, et al. Effectiveness of exercise in hepatic fat mobilization in nonalcoholic fatty liver disease: systematic review. World J Gastroenterol. 2016;22(27):6318-27.
    1. Lee JI, LeeHW, Lee KS, Lee HS, Park JY. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a Nationwide nested case-control study. Am J Gastroenterol 2021;116(1):116-124.
    1. Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, et al. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in nonalcoholic fatty liver disease. Liver Int. 2018;38(10):1793-802.
    1. Tanaka K, Nanbara S, Tanaka T, Koide H, Hayashi T. Aminotransferase activity in the liver of diabetic mice. Diabetes Res Clin Pract. 1988;5(1):71-5.

MeSH terms

LinkOut - more resources